| 彭 睿,和雪梅,杨 敏,黄 敏,李博一.普罗布考联合胰激肽原酶对老年糖尿病周围神经病变患者氧化应激反应及血清NSE水平的影响[J].,2019,19(4):729-733 |
| 普罗布考联合胰激肽原酶对老年糖尿病周围神经病变患者氧化应激反应及血清NSE水平的影响 |
| Effects of Probucol Combined with Kallidinogenase on the Oxidative Stress Reaction and Serum NSE Level in the Elderly Patients with Diabetic Peripheral Neuropathy |
| 投稿时间：2018-08-01 修订日期：2018-08-24 |
| DOI：10.13241/j.cnki.pmb.2019.04.027 |
| 中文关键词: 老年 糖尿病周围神经病变 普罗布考 胰激肽原酶 氧化应激反应 神经元特异性烯醇化酶 |
| 英文关键词: Elderly Diabetic peripheral neuropathy Probucol Kallidinogenase Oxidative stress reaction Neuron specific enolase |
| 基金项目:云南省应用基础研究基金项目(2010CD123) |
|
| 摘要点击次数: 765 |
| 全文下载次数: 470 |
| 中文摘要: |
| 摘要 目的：探讨普罗布考联合胰激肽原酶对老年糖尿病周围神经病变患者氧化应激反应及血清神经元特异性烯醇化酶(NSE)水平的影响。方法：选择2015年8月至2017年8月我院接诊的94例老年糖尿病周围神经病变患者作为本研究对象，通过随机数表法将其分为观察组(n=47)和对照组(n=47)。对照组在常规治疗基础上给予胰激肽原酶治疗，观察组在对照组基础上联合普罗布考治疗，两组均连续治疗12周。比较两组治疗后的临床疗效、治疗前后运动传导速度(MNCV)、感觉传导速度(SNCV)、多伦多临床评分系统(TCSS)评分、血清丙二醛(MDA)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GSH-Px)及NSE水平的变化和不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率为93.62%(44/47)，明显高于对照组[70.21%(33/47)](P＜0.05)；两组正中神经、腓总神经MNCV、SNCV较治疗前均显著延长(P＜0.05)，且观察组正中神经、腓总神经MNCV、SNCV均明显高于对照组(P＜0.05)；两组TCSS评分各内容和总分、血清MDA、NSE水平较治疗前均显著降低(P＜0.05)，且观察组TCSS评分中症状评分、反射评分、感觉评分和总分及、血清MDA、NSE水平均明显低于对照组(P＜0.05)；两组血清超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GSH-Px)水平较治疗前均显著升高(P＜0.05)，且观察组血清SOD、CAT、GSH-Px水平均明显比对照组高(P＜0.05)。两组治疗期间不良反应总发生率分别为10.64%(5/47)、4.26%(2/47)，组间比较差异无统计学意义(P＞0.05)。结论：普罗布考联合胰激肽原酶治疗老年糖尿病周围神经病变患者的效果显著优于单用胰激肽原酶治疗，可更有效改善神经病变程度，其机制可能和缓解氧化应激反应、降低血清NSE水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effects of probucol combined with kallidinogenase on the oxidative stress reaction and the serum neuron specific enolase(NSE) level in the elderly patients with diabetic peripheral neuropathy. Methods: 94 elderly patients of dia- betic peripheral neuropathy who were treated from August 2015 to August 2017 in our hospital were selected as the research objects. The patients were divided into the observation group (n=47) and the control group (n=47) according to the random number table. The control group was treated with kallidinogenase on the basis of routine treatment, while the observation group was combined with probucol on the basis of the control group, both groups were continuous treatment for 12 weeks. The clinical efficacy, the changes of motor conduction velocity (MNCV), sensory conduction velocity (SNCV), Toronto clinical scoring system (TCSS) score, oxidative stress index, serum NSE and adverse reactions of two groups before and after the treatment were compared. Results: After treatment, the total effective rate of observation group was 93.62% (44/47), which was significantly higher than that of the control group[70.21%(33/47)](P＜0.05); the MNCV and SNCV of nervi medianus and nervus peroneus communis of both groups were significantly longer than those before treat- ment(P＜0.05), which were significantly faster in the observation group than those in the control group(P＜0.05); the TCSS scores, serum MDA and NSE levels of both groups were significantly lower than those before treatment(P＜0.05), the symptom score, reflex score, sensation score, total TCSS score, serum MDA and NSE levels of observation group were significantly lower than those in the con- trol group(P＜0.05); the superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were significantly higher than before treatment(P＜0.05), which were significantly higher than those in he control group(P＜0.05). The total incidence of adverse reactions in the two groups was 10.64% (5/47) and 4.26% (2/47) respectively(P＞0.05). Conclusion: Probucol combined with kallidino- genase is superior to kallidinogenase alone for the elderly diabetic peripheral neuropathy with high safety, which can more effectively im- prove the degree of neuropathy. Its intrinsic mechanism may be related to alleviate the oxidative stress reaction and reduce the expression of serum NSE. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
